Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension to Study AVA102670 and AVA102672, to Assess the Long-term Safety and Efficacy of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy on Cognition in Subjects With Mild to Moderate Alzheimer's Disease.

NCT00490568 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00490568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00490568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension to Study AVA102670 and AVA102672, to Assess the Long-term Safety and Efficacy of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy on Cognition in Subjects With Mild to Moderate Alzheimer's Disease.
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Terminated
Start date
August 8, 2007
Completion date
June 1, 2009
Enrollment
1,461 (actual)
Sites
272

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease